In summary, our data indicated that down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells, suggesting that SPAG9 may be a potential target for therapeutic use. This evidence concerns the gene SPAG9 and triple-negative breast carcinoma.